In this Healio Video Perspective from the Retina World Congress, Ashish Sharma, MBBS, MS, gives an update on aflibercept ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...

Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) family members VEGF-A, VEGF-B, and placental growth factor.

Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG. In the U.S., Regeneron maintains exclusive rights to EYLEA and aflibercept 8 mg. Bayer has licensed the exclusive marketing ...

Aflibercept 8mg late-breaking data presented at Retina Society in diabetic macular edema and wet age-related macular degeneration. News release. Regeneron Pharmaceuticals, Inc. November 4, 2022.

EYLEA® (aflibercept) 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO ...

It agreed that aflibercept as well as other anti-VEGF treatments were a substantial improvement over previous treatments, and considered that this improvement applied to the class of drugs. In ...

In both trials, patients treated with aflibercept 8 mg (PULSAR n=673; PHOTON n=491) met the primary endpoint of non-inferiority in vision gains for both the 12- and 16-week dosing regimens after ...